Advertisement

Acta Neuropathologica

, Volume 120, Issue 2, pp 271–273 | Cite as

RAF gene fusions are specific to pilocytic astrocytoma in a broad paediatric brain tumour cohort

  • Andrew R. J. Lawson
  • Ruth G. Tatevossian
  • Kim P. Phipps
  • Simon R. Picker
  • Antony Michalski
  • Denise Sheer
  • Thomas S. JacquesEmail author
  • Tim ForshewEmail author
Correspondence

Brain tumours are the most common solid tumour in children and are the primary cause of cancer-related death in children and young adults [4, 6]. The most prevalent childhood brain tumours are low-grade gliomas, specifically pilocytic astrocytomas (PAs, WHO Grade I) [1]. PAs are slow-growing tumours which are often cystic, and may occur sporadically or in association with the genetic disorder Neurofibromatosis type 1. Several recent studies including our own have identified novel KIAA1549BRAF and SRGAP3RAF1 gene fusions in the majority of PAs tested [3, 7, 8, 12]. In these fusions, the N-terminal auto-inhibitory domains of the RAF proteins are replaced by those of KIAA1549 or SRGAP3, resulting in constitutive activation of the ERK/MAPK pathway. A recent study has suggested that the KIAA1549BRAF fusion is more common in PAs originating in the cerebellum [5]. In low-grade glioma without RAFgene fusions there is increasing evidence for activation of the ERK/MAPK pathway through...

Keywords

Astrocytoma Pilocytic Astrocytoma Local Research Ethic Committee Paediatric Brain Tumour Diffuse Astrocytoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgments

This work was supported by the Samantha Dickson Brain Tumour Trust, Great Ormond Street Hospital Children’s Charity and Cancer Research UK London Research Institute.

Conflict of interest statement

The authors declare that they have no conflict of interest.

Supplementary material

401_2010_693_MOESM1_ESM.pdf (50 kb)
Supplementary material 1 (PDF 49.5 kb)

References

  1. 1.
    CBTRUS (2008) Statistical report: primary brain tumors in the United States, 2000–2004. Published by the Central Brain Tumor Registry of the United StatesGoogle Scholar
  2. 2.
    Dougherty MJ, Santi M, Brose MS et al (2010) Activating mutations in BRAF characterize a spectrum of pediatric low-grade gliomas. Neuro Oncol doi: 10.1093/neuonc/noq007
  3. 3.
    Forshew T, Tatevossian RG, Lawson AR et al (2009) Activation of the ERK/MAPK pathway: a signature genetic defect in posterior fossa pilocytic astrocytomas. J Pathol 218(2):172–181CrossRefPubMedGoogle Scholar
  4. 4.
    Geraci M, Birch JM, Alston RD, Moran A, Eden TO (2007) Cancer mortality in 13 to 29-year-olds in England and Wales, 1981–2005. Br J Cancer 97(11):1588–1594CrossRefPubMedGoogle Scholar
  5. 5.
    Horbinski C, Hamilton RL, Nikiforov Y, Pollack IF (2010) Association of molecular alterations, including BRAF, with biology and outcome in pilocytic astrocytomas. Acta Neuropathol 119(5):641–649CrossRefPubMedGoogle Scholar
  6. 6.
    Horner MJ, Ries LAG, Krapcho M et al (2009) SEER Cancer Statistics Review, 1975-2006. In: National Cancer Institute, http://seer.cancer.gov/csr/1975_2006/, based on November 2008 SEER data submission, posted to the SEER web site
  7. 7.
    Jones DT, Kocialkowski S, Liu L et al (2008) Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res 68(21):8673–8677CrossRefPubMedGoogle Scholar
  8. 8.
    Jones DT, Kocialkowski S, Liu L, Pearson DM, Ichimura K, Collins VP (2009) Oncogenic RAF1 rearrangement and a novel BRAF mutation as alternatives to KIAA1549:BRAF fusion in activating the MAPK pathway in pilocytic astrocytoma. Oncogene 28(20):2119–2123CrossRefPubMedGoogle Scholar
  9. 9.
    Korshunov A, Meyer J, Capper D et al (2009) Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma. Acta Neuropathol 118(3):401–405CrossRefPubMedGoogle Scholar
  10. 10.
    Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (eds) (2007) WHO Classification of tumours of the central nervous system. IARC, LyonGoogle Scholar
  11. 11.
    Sharma MK, Zehnbauer BA, Watson MA, Gutmann DH (2005) RAS pathway activation and an oncogenic RAS mutation in sporadic pilocytic astrocytoma. Neurology 65(8):1335–1336CrossRefPubMedGoogle Scholar
  12. 12.
    Sievert AJ, Jackson EM, Gai X et al (2009) Duplication of 7q34 in paediatric low-grade astrocytomas detected by high-density single-nucleotide polymorphism-based genotype arrays results in a novel BRAF fusion gene. Brain Pathol 19(3):449–458CrossRefPubMedGoogle Scholar
  13. 13.
    Tatevossian RG, Lawson AR, Forshew T, Hindley GF, Ellison DW, Sheer D (2010) MAPK pathway activation and the origins of paediatric low-grade astrocytomas. J Cell Physiol 222(3):509–514PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Andrew R. J. Lawson
    • 1
  • Ruth G. Tatevossian
    • 1
    • 2
  • Kim P. Phipps
    • 3
  • Simon R. Picker
    • 4
    • 5
  • Antony Michalski
    • 6
  • Denise Sheer
    • 1
  • Thomas S. Jacques
    • 4
    • 5
    Email author
  • Tim Forshew
    • 1
    Email author
  1. 1.Queen Mary University of London, Centre for Neuroscience and Trauma, Blizard Institute of Cell and Molecular Science, Barts and the London School of Medicine and DentistryLondonUK
  2. 2.Cancer Research UK London Research InstituteLondonUK
  3. 3.Department of NeurosurgeryGreat Ormond Street Hospital for Children NHS TrustLondonUK
  4. 4.Department of HistopathologyGreat Ormond Street Hospital for Children NHS TrustLondonUK
  5. 5.Neural Development Unit, UCL-Institute of Child HealthUniversity College LondonLondonUK
  6. 6.Department of OncologyGreat Ormond Street Hospital for Children NHS TrustLondonUK

Personalised recommendations